Press release
Deadline coming up on September 23, 2019 in Lawsuit for Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
A Deadline is coming up on September 23, 2019 in the lawsuit for certain investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
Investors who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and there are strict and short deadlines running. Deadline: September 23, 2019. NASDAQ: KPTI stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock during the time period of March 2, 2017 and February 22, 2019, and violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm Therapeutics Inc. (NASDAQ: KPTI common stock in or traceable to the Company's public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018. More specifically, the plaintiff alleges that the Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer, that the, Defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor", and that the Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile”, while in reality, selinexor was unsafe with limited efficacy.
Those who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline coming up on September 23, 2019 in Lawsuit for Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) here
News-ID: 1829853 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investors who lost money with shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) sho …
An investor, who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS), filed a lawsuit over alleged violations of Federal Securities Laws by AST SpaceMobile, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of AST SpaceMobile, Inc. (NASDAQ: ASTS) have certain options and for certain investors are short and strict deadlines running. Deadline: June 17, 2024. NASDAQ: ASTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Sharecare, Inc. (NASDA …
An investor, who purchased shares of Sharecare, Inc. (NASDAQ: SHCR), filed a lawsuit over alleged violations of Federal Securities Laws by Sharecare, Inc.
Investors who purchased shares of Sharecare, Inc. (NASDAQ: SHCR) have certain options and for certain investors are short and strict deadlines running. Deadline: June 18, 2024. NASDAQ: SHCR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Atlanta, GA based Sharecare, Inc. operates as…
More Releases for Karyopharm
Hematological Cancers Market With in-detailed Competitor Analysis, Forecast to 2 …
Global Hematological Cancers Market Overview:-
Stratagem Market Insights has evaluated the global Hematological Cancers market in its latest research report. The research report, titled Global Hematological Cancers Market 2022 by Manufacturers, Regions, Type, and Application, Forecast to 2028, presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of…
Global Pet Cancer Therapeutics Market Size, Trends and Forecast 2027 By | Karyop …
The Pet Cancer Therapeutics Market study provides a thorough but completes analysis of the worldwide Pet Cancer Therapeutics market, including all of the major company profiles that have an impact on the market's growth and breadth. The study is written in accordance with data that could be critical to the market's progress. The study gives the customer a clear picture of the current market's obstacles and issues, and it helps…
DiGeorge Syndrome Drug Market Worth Observing Growth : CELLECTAR BIOSCIENCES, IN …
The DiGeorge Syndrome Drug Market analysis report brings into focus studies about market definition, market segmentation, and competitive analysis in the market. The precise and state-of-the-art information provided via this report helps businesses get aware about the types of consumers, consumer's demands and preferences, their point of view about the product, their buying intentions, their response to particular product, and their varying tastes about the specific product already existing in…
Investigation announced for Long-Term Investors in shares of Karyopharm Therapeu …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Karyopharm Therapeutics Inc..
Investors who are current long term investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: KPTI stocks follows a lawsuit filed against Karyopharm…
Lawsuit filed for Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: K …
An investor, who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), filed a lawsuit over alleged violations of Federal Securities Laws by Karyopharm Therapeutics Inc.
Investors who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and for certain investors are short and strict deadlines running. Deadline: September 23, 2019. NASDAQ: KPTI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Karyopharm Therapeutics Inc…
Hematological Cancers Therapeutics Market To Reach $66.34 Billion By 2026 | Top …
According to the current analysis of Reports and Data, the global hematological cancers therapeutics market accounted for USD 31.32 Billion in 2018 and is expected to reach USD 66.34 billion by 2026 , at a CAGR of 9.8 percent. Hematology Cancer Therapeutics market is majorly driven by a high incidence of blood cancer across the globe and favorable funding scenario for the research and development of therapeutics for blood cancer.…
